Bard1 Life Sciences Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.
|Primary activities||Developing and commercialising cancer diagnostic products.|
|Industry / Sector||Diagnostics & Research / Healthcare|
|Mailing address||23 Normanby Road Notting Hill South Perth WA 3168 Australia|
|Phone / Fax||61 3 9548 7586 /|
|Share registry||COMPUTERSHARE INVESTOR SERVICES PTY LIMITED|
Bard1 Life Sciences does not pay dividends.
As of May 2021, following are the company executives and directors listed on Bard1 Life Sciences.
|Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.||Chief Exec. Officer||417.64k|
|Mr. Peter Lynton Gunzburg B Comm, ASIA||Managing Director||68||82.12k|
|Mr. Tony Di Pietro AGIA, C.A., M.A.I.C.D., B.Com, CPA||CFO & Joint Company Sec.|
|Mr. Carl S. Stubbings||Chief Operating Officer|
|Dr. Peter William French M.B.A., B.Sc., M.Sc., Ph.D., MBA, FRSM||Chief Scientific Officer|
|Ms. Pauline Anne Collinson||Joint Company Sec.||64|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Bard1 Life Sciences is 198.54M and its enterprise value is 192.1M. The enterprise value to revenue ratio of BD1 is 313.77.
Companies similar to Bard1 Life Sciences (BD1)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Bard1 Life Sciences (ASX:BD1) Frequently Asked Questions
1. What is Bard1 Life Sciences's Stock Symbol?
Bard1 Life Sciences trades on ASX under the ticker symbol "BD1".
2. What is Bard1 Life Sciences's stock price today?
One share of BD1 stock can currently be purchased for approximately $2.48.
3. How can I contact Bard1 Life Sciences?
Bard1 Life Sciences's mailing address is 23 Normanby Road Notting Hill South Perth WA 3168 Australia. The company can be reached via phone at 61 3 9548 7586.
4. What is Bard1 Life Sciences's official website?
The official website of Bard1 Life Sciences is http://www.bard1.com.
5. Which share registry manages Bard1 Life Sciences's stock?
Bard1 Life Sciences's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.